Healthcare sector | Medical Devices industry
| Price | $21.85 |
|---|---|
| Shares Outstanding | 57.25M |
| All-Time Low | $9.17 |
| 52-Week Low | $21.00 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-19.84 |
| Net Tangible Assets / Share | $0 |
| Shares Outstanding Ave Change (Annual) | 2.37% |
| Shares Δ YoY | 2.34% |
| Avg CA Burn (Annual %) | -8.28% (as of 3-8-2026) |
| Avg CA Burn (Quarterly %) | 1.41% (as of 3-8-2026) |
| Max Earning Power / Share | $-70.71 |
|---|---|
| Adjusted Earning Power |
$-86.61
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
5.85%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 145.4M (as of 3-8-2026) |
| Avg EBITDA (5Q) | 15.7M (as of 3-8-2026) |
| Avg Net Income (5Y) | -200.1M (as of 3-8-2026) |
| Avg Net Income (5Q) | -377.6M (as of 3-8-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 3-8-2026 |
| Consecutive Years Paid | No | 3-8-2026 |
| Pays Dividend | No | 3-8-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 3-8-2026 |
| Net Income Positive | No | 3-8-2026 |
| Current Dividend Streak | No | 3-8-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $-8.14 | -465.4M ($-465,367,000) | 57.2M (57,194,781) |
| 2025-09-30 | Quarterly | $-8.37 | -478.7M ($-478,669,000) | 57.2M (57,189,761) |
| 2025-06-30 | Quarterly | $-9.54 | -545.1M ($-545,134,000) | 57.2M (57,159,478) |
| 2025-03-31 | Quarterly | $-8.06 | -460.1M ($-460,113,000) | 57.1M (57,118,641) |
| 2024-12-31 | Quarterly | $-8.02 | -447.9M ($-447,876,000) | 55.9M (55,876,517) |
| 2024-12-31 | Annual | $-8.02 | -447.9M ($-447,876,000) | 55.9M (55,876,517) |
| 2024-09-30 | Quarterly | $-8.23 | -459.7M ($-459,703,000) | 55.9M (55,866,099) |
| 2023-12-31 | Annual | $4.22 | 230.1M ($230,136,000) | 54.6M (54,597,142) |
| 2022-12-31 | Annual | $6.52 | 353.8M ($353,770,000) | 54.2M (54,228,619) |
| 2021-12-31 | Annual | $29.36 | 1.5B ($1,529,092,000) | 52.1M (52,083,025) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 2.1B ($2,107,623,000) |
| 2023-12-31 | 1.7B ($1,707,197,000) |
| 2022-12-31 | 1.6B ($1,563,101,000) |
| 2021-12-31 | 1.4B ($1,426,188,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-03-05 | 57,245,131 | +55,750 |
| 2025-11-10 | 57,189,381 | +29,578 |
| 2025-09-17 | 57,159,803 | +3 |
| 2025-08-12 | 57,159,800 | +36,700 |
Latest short-interest change: 8,035,071 shares (21.09% of float) | Days to cover: 6.65
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-11 | 8,035,071 shares | -632,866 | -7.30% |
| 2026-02-26 | 8,667,937 shares | -48,940 | -0.56% |
| 2026-02-11 | 8,716,877 shares | +577,523 | +7.10% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.